Timothy Watkins
Chief Medical Officer & Head of Development Contineum Therapeutics
Seminars
Wednesday 30th September 2026
Panel Discussion: A Year in Review: Charting the Evolving IPF Landscape & Implications for Drug Development
9:30 am
The past year has been transformative for IPF, with new therapies, emerging mechanisms, and evolving patient management strategies reshaping the landscape. This panel will provide a strategic, forward-looking overview of how the field has progressed and what the next 12-18 months may hold. Panellists will discuss the expanding pathophysiology of IPF, emerging classifications of therapies, and implications for patient care, clinical development strategy, and communication with stakeholders.
Key Discussion Points:
- How newly approved therapies and emerging candidates are expected to influence IPF treatment and clinical and research priorities in the next 12–18 months.
- Exploring the practical impact of emerging terminology, anti-fibrotic, anti-inflammatory, de-differentiation, fibrolysis, and how these distinctions may shape patient and clinician preferences
- Approaches for ordering, timing, and combining therapies in a multi-drug era, balancing efficacy, safety, and operational feasibility.
- Identifying opportunities, challenges, and areas for collaboration to ensure trials and programs remain aligned with evolving clinical practice
Wednesday 30th September 2026
Introducing Contineum Therapeutic’s PIPE-791 a Validated LPA1R Antagonist in IPF
6:00 pm
- Targeting the lysophosphatidic acid 1 receptor (LPA1R), a clinically validated driver of f ibrosis, to disrupt fibroblast recruitment, vascular leak, and pro-fibrotic signalling in IPF
- Reviewing preclinical findings and early clinical data supporting PIPE-791, including differentiation strategy within the LPA1R class and considerations for dose, safety, and patient selection
- Evaluating whether next-generation LPA1R antagonism can overcome historical development challenges and how this programme may fit within combination strategies and evolving standards of care
